A new obe­si­ty biotech; Uro­Gen aims to raise $107M

Plus, news about Ot­su­ka, Io­n­is, Abil­i­ty Bi­o­log­ics, San­thera, Mus­tang Bio and Vaxart:

New biotech joins obe­si­ty race: Su­percede Ther­a­peu­tics raised an undis­closed seed round from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.